What is PreciThera?
PreciThera, Inc. is a biotechnology company dedicated to advancing therapies for rare bone diseases. By integrating computational technology with a profound understanding of disease pathology, the company targets heterogeneous genetic disorders characterized by bone dysfunction. PreciThera's approach aims to leverage novel biological insights to create targeted strategies that address the complex symptoms associated with these conditions, offering hope for improved patient outcomes.
How much funding has PreciThera raised?
PreciThera has raised a total of $29M across 1 funding round:
Series A
$29M
Series A (2017): $29M with participation from Emerillon Capital, Arix Bioscience, CTI Life Sciences, Sanderling Ventures, and Fonds de solidarité FTQ
Key Investors in PreciThera
Emerillon Capital
Emerillon Capital is an investment firm that likely focuses on providing capital for companies with high growth potential, particularly within the biotechnology and life sciences sectors, given its association with PreciThera's funding round.
Arix Bioscience
Arix Bioscience is a venture capital firm specializing in the healthcare and life sciences industries, known for investing in and building companies that develop innovative therapeutic solutions.
CTI Life Sciences
CTI Life Sciences Fund is a prominent Canadian venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, with a strong track record in therapeutic development.
What's next for PreciThera?
The substantial enterprise-level backing positions PreciThera for significant growth and advancement in its research and development pipeline. This strategic investment will likely fuel the expansion of its therapeutic programs, potentially enabling the company to move closer to clinical trials and commercialization. PreciThera's focus on rare bone diseases, a niche yet critical area of medical need, suggests a strategic long-term vision for addressing unmet patient needs and establishing a strong market presence in the specialized biotechnology sector.
See full PreciThera company page
